Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Stock Holdings Lowered by Bellevue Group AG

Bellevue Group AG lowered its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 15.4% in the 1st quarter, HoldingsChannel reports. The institutional investor owned 2,055,874 shares of the company’s stock after selling 374,626 shares during the period. Neurocrine Biosciences accounts for approximately 4.3% of Bellevue Group AG’s investment portfolio, making the stock its 3rd biggest holding. Bellevue Group AG’s holdings in Neurocrine Biosciences were worth $283,546,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. First Horizon Advisors Inc. lifted its position in Neurocrine Biosciences by 10.5% during the 4th quarter. First Horizon Advisors Inc. now owns 782 shares of the company’s stock valued at $103,000 after acquiring an additional 74 shares during the period. Quadrant Capital Group LLC lifted its position in Neurocrine Biosciences by 3.9% during the fourth quarter. Quadrant Capital Group LLC now owns 2,075 shares of the company’s stock valued at $273,000 after purchasing an additional 78 shares during the period. Envestnet Portfolio Solutions Inc. boosted its stake in shares of Neurocrine Biosciences by 3.2% in the 4th quarter. Envestnet Portfolio Solutions Inc. now owns 2,530 shares of the company’s stock worth $333,000 after buying an additional 78 shares during the last quarter. Commonwealth Equity Services LLC grew its stake in shares of Neurocrine Biosciences by 0.6% during the 1st quarter. Commonwealth Equity Services LLC now owns 13,941 shares of the company’s stock valued at $1,923,000 after purchasing an additional 84 shares during the period. Finally, Balentine LLC increased its holdings in Neurocrine Biosciences by 4.0% during the fourth quarter. Balentine LLC now owns 2,316 shares of the company’s stock valued at $305,000 after buying an additional 89 shares during the last quarter. 92.59% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Neurocrine Biosciences

In other news, insider Ingrid Delaet sold 273 shares of Neurocrine Biosciences stock in a transaction on Monday, May 6th. The shares were sold at an average price of $140.55, for a total transaction of $38,370.15. Following the completion of the sale, the insider now directly owns 7,507 shares in the company, valued at $1,055,108.85. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In related news, insider Julie Cooke sold 900 shares of the stock in a transaction that occurred on Tuesday, July 16th. The shares were sold at an average price of $150.04, for a total value of $135,036.00. Following the transaction, the insider now owns 18,202 shares in the company, valued at approximately $2,731,028.08. The sale was disclosed in a filing with the SEC, which is available through this link. Also, insider Ingrid Delaet sold 273 shares of Neurocrine Biosciences stock in a transaction that occurred on Monday, May 6th. The shares were sold at an average price of $140.55, for a total transaction of $38,370.15. Following the sale, the insider now owns 7,507 shares of the company’s stock, valued at $1,055,108.85. The disclosure for this sale can be found here. In the last quarter, insiders have sold 80,709 shares of company stock worth $11,009,150. 4.30% of the stock is owned by corporate insiders.

Neurocrine Biosciences Stock Performance

NASDAQ:NBIX traded up $0.70 during mid-day trading on Friday, hitting $146.80. 744,764 shares of the company’s stock traded hands, compared to its average volume of 631,030. The company has a market capitalization of $14.77 billion, a P/E ratio of 40.44 and a beta of 0.37. The company has a fifty day moving average of $139.16 and a 200 day moving average of $137.97. Neurocrine Biosciences, Inc. has a twelve month low of $99.36 and a twelve month high of $150.39.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its quarterly earnings data on Wednesday, May 1st. The company reported $0.42 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.04 by ($0.62). The company had revenue of $515.30 million for the quarter, compared to analyst estimates of $512.21 million. Neurocrine Biosciences had a net margin of 18.65% and a return on equity of 17.45%. On average, research analysts expect that Neurocrine Biosciences, Inc. will post 4.22 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the company. Wells Fargo & Company upgraded Neurocrine Biosciences from an “equal weight” rating to an “overweight” rating and boosted their price objective for the company from $140.00 to $170.00 in a research note on Wednesday, April 24th. Cantor Fitzgerald reissued an “overweight” rating and set a $155.00 price target on shares of Neurocrine Biosciences in a report on Thursday. Wedbush restated an “outperform” rating and issued a $152.00 price objective on shares of Neurocrine Biosciences in a research report on Wednesday, May 29th. Canaccord Genuity Group increased their price objective on shares of Neurocrine Biosciences from $154.00 to $164.00 and gave the company a “buy” rating in a report on Thursday, May 2nd. Finally, StockNews.com cut shares of Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a research report on Saturday. Six investment analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $154.08.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.